Search Results

CG Oncology, Inc. announced that it has initiated an Expanded Access Program for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette-Guerin and meet certain program eligibility criteria.

Following an upsized IPO earlier this year, CG Oncology on Friday posted promising Phase III data for cretostimogene, which elicited a 75% complete response rate in high-risk non-muscle invasive bladder cancer patients.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, reported financial results for the first quarter ended March 31, 2024, and provided business updates.

CG Oncology, Inc., a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, will host a virtual investor event on Friday, May 3, 2024, at 4:30pm EDT.

CG Oncology, Inc. announced that an abstract with final results of CORE-001, its Phase 2 trial of cretostimogene in combination with pembrolizumab, will be presented at the American Society of Clinical Oncology 2024 Annual Meeting, which will take place from May 31-June 4, 2024, at McCormick Place Convention Center, in Chicago, IL.

CG Oncology, Inc. announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.

CG Oncology, Inc. today announced the publication in Nature Medicine of final results from the Company’s CORE-001 Phase 2 trial of cretostimogene plus pembrolizumab in BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NIMBC).

While initial public offering activity was light in 2023, the new year has recorded the first IPO plan—from California-based CG Oncology.

CG Oncology, Inc. announced final results from the Phase 2 CORE-001 clinical trial of its oncolytic immunotherapy candidate, cretostimogene, in combination with pembrolizumab for the treatment of BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ.